KWS BioTest

KWS BioTest
Name	KWS BioTest
Type	Private
Industry	Biotechnology
Founded	1998
Headquarters	Berlin, Germany
Products	Diagnostic assays, preclinical models, GLP testing
Employees	420 (2024)

KWS BioTest is a biotechnology company specializing in preclinical testing, diagnostics, and assay development for agricultural and medical applications. The firm operates contract laboratories and provides regulatory support for clients in seed technology, pharmaceutical research, and agrochemical development. KWS BioTest's operations intersect with institutions, companies, and regulatory bodies across Europe and North America.

Overview

KWS BioTest maintains laboratory facilities in Berlin, Hannover, and Leipzig and offers services to organizations such as Bayer AG, BASF, Syngenta, Monsanto Company, Novartis, Pfizer, Roche, AstraZeneca, GlaxoSmithKline, Merck & Co., Eli Lilly and Company, Sanofi, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Thermo Fisher Scientific, Illumina, Agilent Technologies, Beckman Coulter, Qiagen, Bio-Rad Laboratories, GE Healthcare, Samsung Biologics, Charles River Laboratories International, Inc., Covance, WuXi AppTec, Labcorp, ICON plc, Parexel International, PAREXEL, Novavax, Moderna, Inc., Regeneron Pharmaceuticals, Biogen, Amgen, Gilead Sciences, Becton Dickinson, Sartorius AG, Lonza Group, Cryoport, Eurofins Scientific, SGS S.A., Intertek Group plc, TÜV SÜD, Dekra SE, Federal Institute for Risk Assessment, European Food Safety Authority, European Medicines Agency, Food and Drug Administration, World Health Organization, Organisation for Economic Co-operation and Development, International Organization for Standardization, Deutsche Forschungsgemeinschaft, Max Planck Society, Helmholtz Association, Fraunhofer Society, University of Cambridge, University of Oxford, Harvard University, Massachusetts Institute of Technology, Stanford University.

History and Development

Founded in 1998 by former researchers associated with Max Planck Society, the company expanded through partnerships with firms like Bayer AG and research contracts from European Commission programs. Early growth was influenced by collaborations with academic centers such as University of Göttingen, Technische Universität München, Ludwig Maximilian University of Munich, Charité – Universitätsmedizin Berlin, Humboldt University of Berlin, Free University of Berlin, Leipzig University, University of Halle-Wittenberg, and interactions with agencies including the European Medicines Agency and Food and Drug Administration. KWS BioTest adapted technologies from projects funded by the Horizon 2020 program and participated in consortia with Fraunhofer Society institutes and private contractors like Charles River Laboratories International, Inc. and WuXi AppTec.

Products and Services

KWS BioTest provides diagnostic assays, in vitro and in vivo preclinical models, genotyping services, and GLP-compliant toxicology testing. Clients include multinational firms such as Syngenta, BASF, Bayer AG, and pharmaceutical groups like Pfizer, Novartis, Roche, AstraZeneca, and Merck & Co.. Service lines cover seed trait evaluation commissioned by Monsanto Company and genomic assays compatible with platforms from Illumina, Thermo Fisher Scientific, and Qiagen. Contract research offerings overlap with the portfolios of Covance, ICON plc, Labcorp, Parexel International, and Eurofins Scientific.

Research and Methodologies

KWS BioTest employs a range of methodologies including next-generation sequencing, CRISPR-based assays, high-throughput phenotyping, and computational modeling. Techniques derive from academic work at Max Planck Institute for Plant Breeding Research, John Innes Centre, Cold Spring Harbor Laboratory, Sanger Institute, Broad Institute, European Molecular Biology Laboratory, Wellcome Sanger Institute, Institut Pasteur, Weizmann Institute of Science, ETH Zurich, EPFL, and University of California, Berkeley. The company integrates platforms from vendors including Agilent Technologies, Bio-Rad Laboratories, Beckman Coulter, Sartorius AG, and Lonza Group and implements protocols influenced by publications in journals like Nature, Science, Cell, The Lancet, The New England Journal of Medicine, PLOS ONE, Proceedings of the National Academy of Sciences, and Nature Biotechnology.

Quality Control and Regulatory Compliance

Quality management follows standards set by International Organization for Standardization (ISO) series and Good Laboratory Practice guidelines cited by the Organisation for Economic Co-operation and Development. Regulatory interaction involves submissions to bodies such as the European Medicines Agency, Food and Drug Administration, European Food Safety Authority, and national competent authorities in Germany and other EU states. Audits and certifications have been conducted by firms like TÜV SÜD, Dekra SE, and SGS S.A., and compliance reporting aligns with directives from the European Commission and guidelines from the World Health Organization.

Collaborations and Partnerships

KWS BioTest entered consortia with academic and industrial partners such as Max Planck Society, Fraunhofer Society, Helmholtz Association, University of Cambridge, University of Oxford, Harvard University, Stanford University, University of California, San Francisco, ETH Zurich, EPFL, John Innes Centre, Sanger Institute, Broad Institute, Institut Pasteur, Cold Spring Harbor Laboratory, Charles River Laboratories International, Inc., WuXi AppTec, Covance, Eurofins Scientific, Bayer AG, BASF, Syngenta, and Monsanto Company. These partnerships covered joint research grants under Horizon 2020 and technology transfer projects with corporate partners such as Thermo Fisher Scientific, Illumina, Agilent Technologies, and Qiagen.

Impact and Criticisms

Supporters cite contributions to translational research linking institutions like Max Planck Society and Fraunhofer Society with industry players including Bayer AG and Pfizer, facilitating regulatory submissions to agencies such as the European Medicines Agency and Food and Drug Administration. Critics have raised concerns echoing debates involving Greenpeace, Friends of the Earth, Pew Research Center, Union of Concerned Scientists, European Public Health Alliance, and civil-society organizations about industry influence in preclinical testing, transparency in partnerships with corporations like Monsanto Company and Syngenta, and ethical considerations related to animal testing raised by groups such as People for the Ethical Treatment of Animals and Cruelty Free International. Academic commentators from University of Cambridge, University of Oxford, Harvard University, and Stanford University have published analyses in venues including Nature and Science discussing reproducibility, conflict of interest, and data-sharing standards relevant to the company.

Category:Biotechnology companies